Biotie Therapies - Major shareholder announcements

Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act

BIOTIE THERAPIES CORP.             STOCK EXCHANGE RELEASE       June 17, 2015 at
8.45 p.m.

Notification according to Chapter 9, Section 5 of the Finnish Securities Markets
Act

Biotie Therapies Corp. (the "Company") has today received a notification in
accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from
FMR LLC concerning changes in share ownership described below.

The Company previously announced on June 12, 2015 that it had received a
notification regarding possible changes in holdings from FMR LLC. According to
the previous notification, the entities listed below would, upon the completion
of the Company's U.S. public offering (the "U.S. Offering") and the full
conversion of the convertible notes issued by the Company on May 28, 2015 (the"Convertible Notes") but excluding the over-allotment option for the
underwriters in the U.S. Offering, have a combined holding of shares and votes,
through American Depositary Shares ("ADSs"), that would exceed 5 per cent.

According to the notification received today, following the completion of the
U.S. Offering and the full conversion of the Convertible Notes, which both took
place on June 16, 2015, the entities listed below hold through ADSs in aggregate
66,000,000 shares in the Company, which represent 6.73 per cent of all shares
and votes in the Company. According to the notification, two entities, both for
which FMR CO., INC is the investment manager, have holdings in the Company as
follows:

+------------------------------+-----------+------+------------------+------+
|Fund Name                     |Shares Held|%     |Voting Rights Held|%     |
+------------------------------+-----------+------+------------------+------+
|FID STK SEL SML CAP HC SUB    |13,696,000 |1.3963|13,696,000        |1.3963|
+------------------------------+-----------+------+------------------+------+
|FID SM CP OPPS HEALTH CARE SUB|52,304,000 |5.3325|52,304,000        |5.3325|
+------------------------------+-----------+------+------------------+------+
|TOTAL                         |66,000,000 |6.73  |66,000,000        |6.73  |
+------------------------------+-----------+------+------------------+------+


On the date of this release, the number of shares in the Company amounts to
980,851,935, of which 2,605,691 shares are held by the Company and its
subsidiaries.



In Turku, June 17, 2015

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

David Cook, CFO
Tel. +358 2 2748 900, e-mail: david.cook@biotie.com

DISTRIBUTION:

NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com






[HUG#1929368]